



Blood. 2012 July 12; 120(2): 386–394.

PMCID: PMC3398759

Prepublished online 2012 May 24. doi: [10.1182/blood-2011-12-399667](https://doi.org/10.1182/blood-2011-12-399667)

## Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation

[Michael Roth](#),<sup>1,2</sup> [Britta Will](#),<sup>2</sup> [Guillermo Simkin](#),<sup>2</sup> [Swathi Narayanagari](#),<sup>2</sup> [Laura Barreyro](#),<sup>2</sup> [Boris Bartholdy](#),<sup>2</sup> [Roni Tamari](#),<sup>3</sup> [Constantine S. Mitsiades](#),<sup>4,5</sup> [Amit Verma](#),<sup>3,6</sup> and [Ulrich Steidl](#)<sup>2,3</sup>

[Author information](#) ► [Article notes](#) ► [Copyright and License information](#) ►

This article has been [cited by](#) other articles in PMC.

### Abstract

[Go to](#)

Eltrombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been approved recently for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura. Prior studies have shown that EP stimulates megakaryopoiesis in BM cells from patients with acute myeloid leukemia and myelodysplastic syndrome, and the results also suggested that it may inhibit leukemia cell growth. In the present study, we studied the effects of EP on leukemia cell proliferation and the mechanism of its antiproliferative effects. We found that EP leads to a decreased cell division rate, a block in G<sub>1</sub> phase of cell cycle, and increased differentiation in human and murine leukemia cells. Because EP is species specific in that it can only bind TPO-R in human and primate cells, these findings further suggested that the antileukemic effect is independent of TPO-R. **We found that treatment with EP leads to a reduction in free intracellular iron in leukemic cells in a dose-dependent manner. Experimental increase of intracellular iron abrogated the antiproliferative and differentiation-inducing effects of EP, demonstrating that its antileukemic effects are mediated through modulation of intracellular iron content.** Finally, determination of EP's antileukemic activity in vivo demonstrated its ability to prolong survival in 2 mouse models of leukemia.

### Introduction

[Go to](#)

Survival in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) has remained poor despite recent efforts to treat patients with novel therapeutic regimens.<sup>1–4</sup> In addition, complications secondary to thrombocytopenia and bleeding occur frequently in AML and MDS, leading to significant morbidity and mortality.<sup>5,6</sup> Given that the median age of patients with AML is close to 70 years, novel antileukemia agents with limited BM toxicity are needed to improve outcomes.

Eltrombopag (EP) is an oral, nonpeptide, small-molecule thrombopoietin receptor (TPO-R) agonist that has proven efficacy in treating chronic immune thrombocytopenic purpura (ITP) and hepatitis C–related thrombocytopenia.<sup>7,8</sup> Despite concerns that some leukemia blast cells express TPO-R, we and others have reported previously that EP does not stimulate leukemia or MDS cell growth, but may rather lead to a modest inhibition while continuing to stimulate normal megakaryopoiesis in BM samples of patients with AML or MDS.<sup>9,10</sup> One study using a close chemical derivative of EP found a toxic effect on myeloid leukemia cells, suggesting that the entire substance class, including EP itself, may possess antileukemic activity.<sup>11</sup> Studies using cell lines further suggested that the growth-inhibitory effect of EP is not related to expression levels of TPO-R.<sup>12</sup> However, this hypothesis has not yet been formally tested, and the mechanism through which EP exerts its potential antileukemic effect is not known. The concentrations at which EP inhibits leukemia cell proliferation in vitro are clinically achievable with few side effects and have led to desirable increases in circulating platelet counts in healthy volunteers.<sup>13</sup>

In the present study, we examined the cellular and molecular mechanisms by which EP exerts its antileukemic effect using both in vitro and in vivo models of AML. We show that EP has a profound leukemia-inhibitory effect that is independent of TPO-R in vitro and in vivo, that EP leads to an induction of myeloid differentiation, and that these effects are mediated by a reduction of intracellular iron levels by EP.

## Methods

[Go to](#)

### Reagents

EP (SB-497115) was dissolved as a 1 mg/mL stock solution in distilled water and stored light protected at room temperature for up to 2 weeks. Salicylaldehyde isonicotinyl hydrazine (SIH) was a generous gift of Dr Katherine Franz (Duke University, Durham, NC). Deferoxamine mesylate (DFO), ferrous ammonium citrate, and N-acetyl-L-cysteine were from Sigma-Aldrich. Recombinant human and mouse TPO were from Invitrogen.

### Cell culture

HL60, U937, and HS5 cells were cultured in RPMI medium (CellGro) with 10% FBS (Gemini; at 37°C. Upstream regulatory element (URE) murine AML cells were obtained from PU.1-knockdown mice with targeted disruption of the distal enhancer (URE) –14 kb upstream of the PU.1 gene.<sup>14,15</sup> URE cells were maintained in M5300 medium (StemCell Technologies) supplemented with 10% heat-inactivated FBS, 15% supernatant of WEHI-3B culture medium, 15% supernatant of baby hamster kidney culture medium, and penicillin/streptomycin.

### Cell-proliferation assays

For 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assays, cells were plated into 96-well plates with 100 µL of culture medium. After 72 hours, cells were incubated with 10 µL of MTS reagent (CellTiter 96 AQueous One Solution Cell Proliferation Assay kit; Promega), OD<sub>490</sub> and OD<sub>650</sub> were detected by a microplate reader (VersaMAX; Molecular Devices). The MTS proliferative index was calculated by subtracting the background from raw values, defined as: (OD<sub>490</sub> – OD<sub>650</sub> of a well with cells) – (OD<sub>490</sub> – OD<sub>650</sub> of a well with medium only). Manual cell counts were performed culturing 2 × 10<sup>5</sup> cells/mL in 12-well plates. Viable cells were counted using trypan blue exclusion. Doxorubicin and cytarabine were from Hospira.

### Intracellular iron-detection assays

HL60, URE, and U937 cells were harvested and resuspended in RPMI medium supplemented with 10% FBS and 250nM calcein-AM (Invitrogen) and incubated for 5 minutes at 37°C. Cells were washed and resuspended in prewarmed culture medium. Cells were then left untreated or were treated with EP, TPO, SIH, or DFO for 1 or 4 hours. Intracellular calcein fluorescence was measured by flow cytometry on a FACSARIA II (BD Biosciences) and mean fluorescence was calculated by Diva Version 6.1.3 software (BD Biosciences). Transferrin receptor expression was measured by FACS analysis using Abs against human CD71 (11071973; eBiosciences) and murine CD71 (557416; BD Pharmingen).

### Cell-cycle assays

The Click-iT EdU Flow Cytometry Assay system (Invitrogen) was used following the manufacturer's instructions. Briefly, after culture of cells with 5-ethynyl-2'-deoxyuridine (10µM) for 2 hours, cells were fixed by 4% paraformaldehyde, treated with saponin-containing buffer, and then incubated with Alexa Fluor 647 dye azide. 4',6-diamidino-2-phenylindole was added immediately before flow cytometric analysis.

### Cell-division assays

The Cell Tracker Orange Assay (Invitrogen) was used following the manufacturer's instructions. Briefly, cells were labeled with cell tracker at a concentration of 10µM via incubation at 37°C for 30 minutes. Cells were washed, maintained in culture, and analyzed by FACS every 24 hours.

### Differentiation assays

Cell differentiation was assessed 72 hours after treatment. Morphology was examined after Diff Quik (IMEB) staining and FACS analysis using Abs directed against CD11b (555389; BD Pharmingen) and CD14 (MHCD1406; Invitrogen) for human cell lines, and CD11b (12011282; eBiosciences) for murine cell lines. Morphology was evaluated and documented using an Axiovert 200M microscope with an AxioCam color camera at 37°C (Zeiss).

### Intracellular ROS assays

FACS analysis was used to determine the level of intracellular reactive oxygen species (ROS) in response to various treatments. Briefly, HL60, URE and U937 cells were loaded with 5  $\mu$ M H<sub>2</sub>DCFDA (Invitrogen) for 30 minutes, washed, and evaluated by flow cytometry.

### In vivo leukemia models

All animal experiments were performed in compliance with institutional guidelines and approved by the Animal Institute Committee of the Albert Einstein College of Medicine (protocol number 20110102).

NOD-SCID IL-2R $\gamma$ -null (NSG) mice were sublethally irradiated (200 rad) and intravenously inoculated with 1  $\times$  10<sup>6</sup> URE cells. At day +3, mice were divided into 3 groups: group 1 received untreated drinking water, group 2 received drinking water with 0.4 mg/mL of EP, and group 3 received 1.0 mg/mL of EP in the drinking water. The untreated and treated water was changed every 3 days. Mice were monitored for signs of leukemia and their BM and spleens were harvested at death. For experiments with human leukemia cells, NSG mice were sublethally irradiated (200 rad) and intravenously inoculated with 1  $\times$  10<sup>7</sup> HL60 cells. At day +3, mice were divided into 3 groups: group 1 received untreated drinking water, group 2 received drinking water with 1.0 mg/mL of EP, and group 3 received 3.0 mg/mL of EP. The untreated and treated water was changed twice every week. Mice were monitored, assessed for engraftment, and their BM and spleens were harvested at death. Engraftment was assessed by FACS analysis using Abs directed against murine CD45.1 (12045383; eBiosciences) and human CD15 (11015973; eBiosciences).

### Microarray experiments and analysis

RNA was extracted from HL60 cells after 12 and 36 hours of treatment with EP, or without treatment using TRIzol reagent (Invitrogen). After evaluation of the quality of RNA with an Agilent 2100 Bioanalyzer, RNA was labeled with the GeneChip WT terminal labeling kit (Affymetrix) and labeled cRNA of each individual sample was hybridized to Affymetrix Humane Gene 1.0ST microarrays (Affymetrix), stained, and scanned by the GeneChip Scanner 3000 7G system (Affymetrix) according to standard protocols. The complete array data are deposited in the Gene Expression Omnibus as accession number [GSE37580](#).

### Statistical analysis


Results are reported as the means  $\pm$  SD. The Student *t* test was used to determine statistical significance in the in vitro experiments. *P* < .05 was considered statistically significant. For in vivo experiments, the log-rank test was used to determine statistical significance of observed differences in overall survival.

## Results

[Go to](#) 

### EP leads to a decreased cell division rate and a block in the G<sub>1</sub> phase of the cell cycle in human and murine leukemia cells

We evaluated the dose of EP required to inhibit HL60 cell (human) and URE cell (murine) proliferation. A murine cell line was evaluated in all experiments because EP is highly species specific and does not activate the TPO-R pathway in murine cells.<sup>16</sup> HL60 cells and URE cells were incubated with increasing concentrations of EP for 72 hours. Manual cell counts and MTS assays were performed every 24 hours. **EP inhibits HL60 cells and URE cells (Figure 1A) in a dose-dependent manner at in vitro concentrations that are achievable in vivo.**<sup>13,17</sup> To evaluate the effect of EP on the rate of cell division, HL60 cells and URE cells were labeled with Cell Tracker Orange (Invitrogen) and cells were analyzed by FACS every 24 hours for 3 days. EP slowed the cell -division rate by 48 hours of treatment in both human HL60 cells and murine URE cells ([Figure 1Bi-iv](#)).



**Figure 1**

**EP inhibits cell cycling and leads to a block in the G<sub>1</sub> phase.** (A)

HL60 and URE cells were treated with increasing concentrations of EP.


Cell viability was measured by cell counts with trypan blue exclusion (top panel), and MTS assays (bottom panel) were ...

Given the effect seen on cell division, we next investigated whether EP-induced changes in the cell cycle that could contribute to slowed cell division. After 48 hours, EP treatment led to a block in the G<sub>1</sub> phase (increase from 30.1%-54.0%; *P* = .02) with a subsequent decrease in the S phase (64.5% for untreated vs 29.5% for EP-treated; *P* = .02) in both HL60 cells and URE cells (increase of cells in G<sub>1</sub> from 50.0%-69.1%, *P* = .01; decrease

of cells in S phase from 43.7%-25.0%,  $P < .001$ ; [Figure 1Ci-ii](#)). Consistent with these findings, gene-expression analysis by microarray of HL60 cells performed 36 hours after EP treatment showed the down-regulation of genes important for the transition from the G<sub>1</sub> to the S phase compared with untreated cells ([Figure 1D](#) and supplemental Figure 1A-B, available on the *Blood* Web site; see the Supplemental Materials link at the top of the online article). To confirm that the effect of EP on cell division and cell cycling was consistent in other human cell lines, EP was tested in U937 cells. Supporting our findings, EP slowed cell division and led to a block in the cell cycle in the G<sub>1</sub> phase in U937 cells (supplemental Figure 2).

#### EP induces differentiation of leukemia cell lines

We also investigated the effect of EP on differentiation. HL60 cells were incubated without EP, with 5 µg/mL of EP, or with TPO for 72 hours and cytopspins were performed followed by Diff Quik staining. HL60 cells treated with EP showed clear signs of differentiation, significant changes in the organization of the nuclear contents, and an increase in the cytoplasm/nucleus ratio, whereas TPO did not induce significant morphologic changes ([Figure 2A](#)). FACS analysis confirmed that EP differentiates HL60 cells with significant increases in the mature myeloid markers CD11b (2.98-fold;  $P < .001$ ) and CD14 (1.61-fold;  $P = .003$ ; [Figure 2Bi-iv](#)).



[Figure 2](#)


#### EP induces differentiation of leukemia cell lines. (A)

Representative morphology of HL60 cells treated for 72 hours without EP, with EP, or with TPO shown at 20× (left panel) and 63× (right panel). Cells treated with EP portray reorganization ...

We also evaluated whether EP induces differentiation of another human cell line (U937 cells) and murine URE leukemia cells. At 72 hours after EP treatment, both cell lines showed significant differentiation-associated morphologic changes with increased cell size and the formation of vacuoles within the cytoplasm of U937 cells ([Figure 2C](#)). EP caused an increase in CD11b (2.25-fold;  $P = .007$ ), which was consistent with a premacrophage state in U937 cells, and also caused an increase in CD11b in URE cells (1.15-fold;  $P = .04$ ; [Figure 2D](#)).

#### EP reduces intracellular iron in leukemia cells

After treatment with EP, gene-expression arrays of HL60 cells showed an overexpression of the transferrin receptor (CD71), which is required for iron transport. This increase in CD71 expression was validated by FACS ([Figure 3D](#)). Given the overexpression of CD71 and the knowledge that EP shares structural similarities to well-described metal chelators, we hypothesized that some of the observed cell biologic effects of EP could be mediated by reduction of intracellular iron (supplemental Figure 3). To address this hypothesis, we evaluated the effect of EP on intracellular iron levels.<sup>18,19</sup> HL60 cells were loaded with the intracellular iron-binding compound calcein-AM (Invitrogen). When bound to Fe<sup>2+</sup>, the fluorescent signal of calcein-AM is quenched; however, on release from Fe with addition of an iron chelator, its fluorescent signal intensifies. After calcein-AM loading, HL60 cells were treated with various concentrations of EP, TPO (as a negative control), SIH (a highly potent iron chelator), or a high concentration of DFO (as another positive control). After 1 hour of treatment, 5 and 10 µg/mL of EP significantly increased calcein-AM fluorescence by 4.48% ( $P = .03$ ) and 8.03% ( $P = .004$ ), respectively, indicating reductions of free intracellular iron in cells treated with EP ([Figure 3A](#)). After 4 hours of treatment, concentrations as low as 1 µg/mL of EP increased the labile intracellular iron pool by 5.12% ± 0.79% ([Figure 3A](#)). Interestingly, treatment with 10 µg/mL of EP (a pharmacologically achievable concentration) resulted in even greater intracellular iron reduction (23.5%;  $P = .003$ ) than the highly potent chelator SIH ([Figure 3A](#)). To determine whether reduction of intracellular iron is a consistent feature of EP across multiple leukemia cell lines, 5 additional cell lines were tested (4 human and 1 murine). All cell lines displayed significant intracellular iron reduction after treatment with 5 µg/mL of EP ([Figure 3B](#)).



[Figure 3](#)


#### EP depletes intracellular iron in leukemia cell lines. (A) HL60

cells were labeled with a 0.25µM concentration of the intracellular iron-chelating dye calcein-AM for 5 minutes. Cells were washed then treated with 0 µg/mL of EP, 5 µg/mL ...

Consistent with the finding that EP chelates intracellular iron, gene-expression analysis at 12 and 36 hours after EP treatment showed that the cells were responding to iron depletion by up-regulating the transferrin receptor (CD71) and down-regulating the ferritin light and heavy chains (Figure 3C). The transferrin receptor transports iron intracellularly, whereas ferritin stores iron when it is in excess. In addition, we found CD71 surface antigen in both HL60 and URE cells to be overexpressed as early as 24 hours after treatment with EP (Figure 3D). To show that CD71 expression is increased in response to EP-induced iron deprivation, HL60 cells were preloaded with iron using ferrous ammonium citrate and subsequently treated with EP. Consistent with our hypothesis, cells loaded with iron and treated with EP showed decreased expression of CD71 compared with cells treated only with EP (Figure 3D). To assess whether iron depletion is characteristic of other TPO agonists, we assessed the ability of a peptidyl TPO agonist to deplete intracellular iron. Four hours after treatment with high-dose Romiplostim, no significant reduction in iron was observed (supplemental Figure 4).

#### **Inhibition of leukemia cell proliferation and induction of differentiation by EP is mediated by a reduction of intracellular iron**

The mechanism by which EP inhibits leukemia cell growth has not been well characterized. Given that EP leads to a reduction of intracellular iron and that iron chelators have been shown to have antiproliferative effects in myeloid leukemia cells, we investigated whether the antileukemic effect of EP is secondary to its ability to deplete intracellular iron. We performed iron-rescue experiments by preloading HL60 cells with 500  $\mu\text{g/mL}$  of ferric ammonium citrate for 24 hours, which resulted in a  $9.76\% \pm 2.10\%$  increase in intracellular iron. HL60 cells were subsequently left untreated (control) or were treated with EP, TPO (negative control), or DFO (positive control). Preloading cells with iron resulted in a rescue from the antiproliferative effects of EP as determined by cell count (95% growth restoration;  $P < .01$ ) and MTS assay after 72 hours (Figure 4A). We made very similar observations in murine leukemia cells: iron-loaded URE cells were also rescued from the antiproliferative effects of EP (84% growth restoration;  $P < .01$ ; Figure 4B).



**Figure 4**

**EP-induced cell death is iron dependent.** (A) HL60 cells were untreated or treated with 5  $\mu\text{g/mL}$  of TPO, 25 ng/mL of EP, or 100u DFO for 72 hours preloaded or not with 500  $\mu\text{g/mL}$  of ferric ammonium citrate (FAC) for 24 hours. Cell viability ...

To assess whether the inhibition of the cell-division rate by EP could also be rescued by increasing the intracellular iron content of HL60 cells, ferric ammonium citrate was preloaded into cells for 24 hours, followed by Cell Tracker labeling of HL60 cells. At 48 hours after EP treatment, cell division was significantly greater in cells preloaded with iron and treated with EP compared with cells only treated with EP (Figure 4C). Similarly, the ability of EP to differentiate HL60 cells was reduced by preloading the cells with iron, as shown by morphologic changes (Figure 4D) and cell-surface expression of CD11b and CD14 (Figure 4E). The morphologic changes induced by EP in HL60 cells were similar to changes induced by treatment with DFO. These findings show that the leukemia-inhibitory and differentiation-inducing effects of EP are mediated by a reduction of intracellular iron.


Knowing that ROS levels vary with intracellular iron levels and that iron chelators have been shown to induce ROS formation, we investigated whether EP also induces ROS.<sup>20</sup> We used  $\text{H}_2\text{DCFDA}$  (Invitrogen) with flow cytometry to assess intracellular ROS levels. HL60, URE, and U937 cells were treated with 5  $\mu\text{g/mL}$  of EP for 1 hour and then incubated with 5  $\mu\text{M}$   $\text{H}_2\text{DCFDA}$ . All cell lines showed significant increases in ROS formation after only 1 hour of treatment (supplemental Figure 5A-B). To determine whether ROS generation was involved in EP-induced differentiation of HL60 cells, we incubated the cells with the antioxidant N-acetyl-L-cysteine during EP treatment, which resulted in a 92% rescue of ROS activity (supplemental Figure 5C). CD11b and CD14 expression ( $-22.1\%$ ,  $P = .045$  and  $-23.6\%$ ,  $P = .01$ , respectively) both decreased in antioxidant-treated cells treated with EP compared with cells treated with EP alone (supplemental Figure 5D).

#### **EP prolongs survival in mouse models of leukemia**

Given the in vitro antileukemic effect of EP, we next evaluated the effect of EP in murine transplantation models of leukemia. Ten million HL60 cells were IV injected into NSG mice via the tail vein and mice were treated starting at day +3 with 1.0 mg/mL of EP in the drinking water or with untreated drinking water. BM aspirations at day +21 showed that mice treated with EP had significantly lower donor cell chimerism (5.6% vs



21.1%;  $P = .03$ ; [Figure 5Ai](#)). EP treatment significantly improved survival in these mice ( $P = .05$ ; [Figure 5Aii](#)), and engrafted leukemia cells in EP-treated mice showed increased CD11b and CD14 expression (supplemental Figure 6), consistent with our observations in vitro. Given that high doses of EP have been well tolerated in humans, we assessed the effect of higher-dose EP in our HL60 leukemia mouse model. Mice treated with 3.0 mg/mL of EP in the drinking water showed significantly increased median survival compared with control mice and mice treated with 1.0 mg/mL of EP, respectively ( $P < .01$ ; [Figure 5Aii](#)).



**Figure 5**

**EP prolongs survival in mouse models of leukemia.** (A) Ten million HL60 cells were transplanted into the tail veins of NSG mice ( $n = 10$ ) 4 hours after sublethal irradiation. Mice were divided into 2 groups, one receiving untreated drinking water, and the ...

We next assessed the effect of EP in NSG mice transplanted with URE leukemia cells. One million URE cells were IV injected via the tail vein in NSG mice. Mice were then treated starting at day +3 with 0.4 or 1.0 mg/mL of EP in the drinking water or with untreated drinking water. We have previously shown that treatment with 0.3 mg/mL of EP in the drinking water results in EP serum levels greater than 2  $\mu\text{g/mL}$ .<sup>10</sup> EP showed a dose-dependent, statistically significant (0.4 mg/mL of EP,  $P = .005$ ; 1.0 mg/mL of EP,  $P = .002$ ) effect on the survival of mice with URE cell leukemia ([Figure 5B](#)), once again demonstrating the leukemia-inhibitory effect of EP in vivo.

We assessed the effect of EP given in combination with standard AML chemotherapeutic agents. HL60 cells were incubated with EP with or without cytarabine or doxorubicin. Manual cell counts at 72 hours showed the addition of EP significantly enhanced the antiproliferative effects of cytarabine and doxorubicin ( $P = .002$  and  $P = .005$ , respectively; [Figure 5Ci-ii](#)).

Finally, given that stromal cells in multiply transfused patients are often iron overloaded and may mitigate the antileukemic effect of EP, we performed coincubation experiments in vitro. Human HS5 stromal cells were preloaded with iron or mock treated for 72 hours and then coincubated with HL60 cells with or without EP treatment. Neither untreated nor iron-overloaded stromal cells alleviated the inhibitory effect of EP on HL60 cell proliferation (supplemental Figure 7).

## Discussion

[Go to](#)

In the present study, the nonpeptide, small-molecule TPO-R agonist EP inhibits leukemia cell growth by depletion of intracellular iron. EP is currently being investigated in clinical trials as a treatment for thrombocytopenia in patients with MDS, and this new discovery that EP reduces intracellular iron provides support that EP may be a promising adjuvant agent for patients with AML and MDS for several reasons. First, the majority of patients with AML and MDS are over the age of 60 years and thus many patients are not able to tolerate intensive chemotherapy and transplant conditioning regimens.<sup>4–6</sup> In addition, many patients with AML and MDS are transfusion dependent and suffer from iron overload. Finally, many patients endure significant morbidity and mortality related to thrombocytopenic bleeding in MDS. An agent such as EP that has an antileukemic effect and does not induce thrombocytopenia, but rather stimulates megakaryopoiesis and platelet production, has the potential to decrease clinically significant thrombocytopenic bleeding and thus improve survival.

Our in vitro studies demonstrate that EP inhibits leukemia cell growth through induction of differentiation, as well as slowed cell division mediated by inhibition of the cell-cycle transition from the  $G_1$  to the S phase. These observations are similar to and consistent with prior studies describing the antileukemic effects of known iron chelators and differentiating agents.<sup>20–26</sup> Studies show that iron chelators have anticancer effects in a variety of malignancies, including breast cancer and melanoma, as shown in patients and solid tumor xenograft models.<sup>25,27,28</sup> It is unclear which exact molecular pathways mediate the antileukemic effects of EP-induced reduction of intracellular iron. Our present data suggest that down-regulation of cell-cycle-promoting genes and/or an increase of ROS may play a role. However, nearly complete rescue of ROS with N-acetyl-L-cysteine resulted only in a partial rescue from the differentiating effects of EP, suggesting that ROS is not the sole pathway mediating differentiation. Further mechanistic studies will be required to understand the precise molecular and functional sequelae of EP treatment in leukemia cells. It will also be important to further

understand how EP interacts with traditional chemotherapy agents, because it would likely be given clinically in conjunction with other cytotoxic therapies. Given the ability of EP to reduce intracellular iron and inhibit growth in leukemia cells, it also seems promising to evaluate the antiproliferative or differentiating effects of EP in other malignancies.

Previous studies have shown that TPO-R is present on a significant percentage of AML cells and that TPO may stimulate blast cells expressing TPO-R.<sup>29–31</sup> Recent studies have postulated that the antileukemic effect of EP is independent of the TPO-R pathway by demonstrating that the effect of EP in leukemia and lymphoma cells lines was not related to the level of TPO-R expression.<sup>12</sup> In addition, a peptibody that stimulates platelet production through TPO-R may stimulate blast production and the transformation from MDS to AML in patients with low-risk MDS.<sup>32</sup> In the present study, we demonstrate that the ability of EP to reduce intracellular iron is not a mechanism shared by the peptibody TPO-R agonist (supplemental Figure 3), and show for the first time that the antileukemic effect of EP is not related to the TPO-R pathway. It has been shown previously that EP interacts with the transmembrane domain of TPO-R and that this interaction and consecutive TPO-R downstream signaling is highly species specific, occurring only in humans and primates and not in murine cells.<sup>16</sup> Our present finding of growth inhibition and differentiation of murine leukemia by EP in vitro and in vivo demonstrates that these effects are TPO-R independent.

The design of small-molecule, nonpeptidyl TPO mimics was originally based on the premise that these molecules have 3 main features: a lipophilic end, an acidic end, and a chelator backbone (supplemental Figure 2).<sup>33,34</sup> The structure of EP has these 3 elements and supports the ability of EP to reduce intracellular iron and potentially other polyvalent cations.<sup>35,36</sup> Given that EP has a chelator backbone that is not iron specific, it is likely that EP chelates other polyvalent cations such as zinc and copper.<sup>36</sup> These cations are required for the function of a variety of important regulatory proteins and have been shown to play a role in cancer growth. Further studies are warranted to determine their contribution to EP-induced inhibition of leukemia cells and potentially other malignancies.

A recent double-blind, placebo-controlled, randomized dose-escalation study showed that maximum serum concentrations of EP of more than 20 µg/mL are clinically achievable with minimal toxicity.<sup>13</sup> These levels are equal to or higher than the levels at which EP reduced intracellular iron and exhibited potent antileukemia effects in our in vitro experiments and in vivo mouse models.<sup>10</sup> Interestingly, BM suppression and anemia have not been reported in patients receiving EP,<sup>7,8,17</sup> supporting the selective anticancer effect of iron chelators and the ability of normal hematopoietic cells to better tolerate iron depletion compared with malignant cells.<sup>10,37,38</sup>

The properties of EP may prove important as both an adjuvant anticancer therapy and as a supportive care agent, potentially improving platelet counts and platelet recovery in patients receiving BM-suppressive treatments and reducing excess iron in multiply transfused patients.<sup>39</sup> The results of the present study provide the basis to further study EP in MDS and AML patients and to consider exploring its effectiveness in other cancers.

## Supplementary Material

[Go to](#)

### Supplemental Figures:

[Click here to view.](#)

## Acknowledgments

[Go to](#)

The authors thank the staff of the Stem Cell FACS and Xenotransplantation Facility (supported by NYSTEM, C024172) and the Albert Einstein Genomics Core Facility.

This work was supported by an American Cancer Society/J. T. Tai & Company postdoctoral fellowship (to B.W.). U.S. is the Diane and Arthur B. Belfer Faculty Scholar in Cancer Research of the Albert Einstein College of Medicine and is the recipient of a Howard Temin Award of the National Cancer Institute (R00CA131503) and a Medical Research Award of the Gabrielle's Angel Foundation for Cancer Research.

## Footnotes

[Go to](#)

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

## Authorship

[Go to](#)

Contribution: M.R. designed the experiments, performed most of the experiments, analyzed the data, and wrote the manuscript; B.W. contributed to the design of experiments, performed the experiments, analyzed the data, and reviewed the manuscript; G.S. and R.T. performed the experiments and analyzed the data; S.N. performed the experiments; L.B. designed the experiments and reviewed the manuscript; B.B. analyzed the data and wrote and reviewed the manuscript; C.S.M. and A.V. contributed to the design of experiments, analyzed the data, and reviewed the manuscript; and U.S. designed the research, supervised the study, analyzed the data, and wrote the manuscript.

Conflict-of-interest disclosure: A.V. and U.S. are the recipients of funding from GlaxoSmithKline for research different from the research reported in this manuscript. The remaining authors declare no competing financial interests.

Correspondence: Ulrich Steidl, Department of Cell Biology, Chanin Bldg No. 606, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461; e-mail: [ulrich.steidl@einstein.yu.edu](mailto:ulrich.steidl@einstein.yu.edu).

## References

[Go to](#)

1. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. *N Engl J Med*. 2009;361(13):1249–1259. [\[PubMed\]](#)
2. Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. *Blood*. 2011;117(8):2366. [\[PubMed\]](#)
3. Petersdorf S, Kopecky K, Stuart R, et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to postconsolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia [abstract]. *Blood (ASH Annual Meeting Abstracts)* 2009;114:790.
4. Rowe JM, Tallman MS. How I treat acute myeloid leukemia. *Blood*. 2010;116(17):3147. [\[PubMed\]](#)
5. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. *Cancer*. 2007;109(9):1705–1714. [\[PubMed\]](#)
6. Konstantopoulos K, Lauren L, Hast R, Reizenstein P. Survival, hospitalization and cause of death in 99 patients with the myelodysplastic syndrome. *Anticancer Res*. 1989;9(4):893. [\[PubMed\]](#)
7. Bussel J, Cheng G, Saleh M, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. *N Engl J Med*. 2007;357(22):2237. [\[PubMed\]](#)
8. McHutchison J, Dusheiko G, Shiffman M, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. *N Engl J Med*. 2007;357(22):2227. [\[PubMed\]](#)
9. Mavroudi I, Pyrovolaki K, Pavlaki K, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. *Leuk Res*. 2011;35(3):323–328. [\[PubMed\]](#)
10. Will B, Kawahara M, Luciano J, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. *Blood*. 2009;114(18):3899. [\[PMC free article\]](#) [\[PubMed\]](#)
11. Kalota A, Gewirtz AM. A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells. *Blood*. 2010;115(1):89. [\[PubMed\]](#)
12. Erickson-Miller C, Kirchner J, Aivado M, May R, Payne P, Chadderton A. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. *Leuk Res*. 2010;34(9):1224–1231. [\[PubMed\]](#)



13. Matthys G, Park JW, McGuire S, et al. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers. *J Clin Pharmacol*. 2011;51(3):301.[[PubMed](#)]
14. Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU. 1. *Nat Genet*. 2004;36(6):624–630.[[PubMed](#)]
15. Steidl U, Rosenbauer F, Verhaak R, et al. Essential role of Jun family transcription factors in PU. 1 knockdown-induced leukemic stem cells. *Nat Genet*. 2006;38(11):1269–1277.[[PubMed](#)]
16. Erickson-Miller C, Delorme E, Tian S, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. *Stem Cells*. 2009;27(2):424–430. [[PMC free article](#)][[PubMed](#)]
17. Jenkins J, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. *Blood*. 2007;109(11):4739.[[PubMed](#)]
18. Conde P. Fluorescence reactions of erichrome red b with metals. Part I: detection of Be, Mg, Al, In, Ga, and Zn. *Analytica Chimica Acta*. 1974;73(1):191–193.
19. Fisher AEO, Naughton D. Zinc (II) complex of the EDTA bis (tyrosine) chelating agent. *J Structural Chem*. 2007;48(4):711–714.
20. Callens C, Coulon S, Naudin J, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. *J Exp Med*. 2010;207(4):731. [[PMC free article](#)][[PubMed](#)]
21. Fu D, Richardson DR. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. *Blood*. 2007;110(2):752.[[PubMed](#)]
22. Lipiński P, Drapier JC, Oliveira L, Retmaska H, Sochanowicz B, Kruszewski M. Intracellular iron status as a hallmark of mammalian cell susceptibility to oxidative stress: a study of L5178Y mouse lymphoma cell lines differentially sensitive to H<sub>2</sub>O<sub>2</sub>. *Blood*. 2000;95(9):2960.[[PubMed](#)]
23. Mladenka P, Šimunek T, Hübl M, Hrdina R. The role of reactive oxygen and nitrogen species in cellular iron metabolism. *Free Radic Res*. 2006;40(3):263–272.[[PubMed](#)]
24. Pahl PMB, Horwitz LD. Cell permeable iron chelators as potential cancer chemotherapeutic agents. *Cancer Invest*. 2005;23(8):683–691.[[PubMed](#)]
25. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. *Proc Natl Acad Sci U S A*. 2006;103(40):14901. [[PMC free article](#)][[PubMed](#)]
26. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. *Blood*. 2009;113(16):3655–3665. [[PMC free article](#)][[PubMed](#)]
27. Rao VA, Klein SR, Agama KK, et al. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. *Cancer Res*. 2009;69(3):948.[[PubMed](#)]
28. Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. *Blood*. 2004;104(5):1450.[[PubMed](#)]
29. Chou FS, Mulloy JC. The Thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis. *J Cell Biochem*. 2011;112(6):1491–1498.[[PubMed](#)]
30. Sitnicka E, Lin N, Priestley G, et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. *Blood*. 1996;87(12):4998.[[PubMed](#)]
31. Wetzler M, Baer M, Bernstein S, et al. Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy. *J Clin Oncol*. 1997;15(6):2262.[[PubMed](#)]
32. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. *J Clin Oncol*. 2010;28(3):437.[[PubMed](#)]

33. Duffy KJ, Price AT, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho [1, 2-d] imidazole thrombopoietin mimics. *J Med Chem.* 2002;45(17):3576–3578.[\[PubMed\]](#)
34. Duffy KJ, Shaw AN, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics. *J Med Chem.* 2002;45(17):3573–3575.[\[PubMed\]](#)
35. Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. *Exp Hematol.* 2005;33(1):85–93.[\[PubMed\]](#)
36. Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. *Clin Ther.* 2009;31(4):764–776.[\[PubMed\]](#)
37. Richardson D, Kalinowski D, Lau S, Jansson P, Lovejoy D. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. *Biochim Biophys Acta.* 2009;1790(7):702–717.[\[PubMed\]](#)
38. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. *Biochim Biophys Acta.* 1997;1331(1):1.[\[PubMed\]](#)
39. Kellum A, Jagiello-Gruszfeld A, Bondarenko I, Patwardhan R, Messam C, Mostafa Kamel Y. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. *Curr Med Res Opin.* 2010;26(10):2339–2346.[\[PubMed\]](#)

---

Articles from Blood are provided here courtesy of **American Society of Hematology**